| Bioactivity | LT-630 is a HDAC6 inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage[1]. |
| Invitro | LT-630 (2-8 nM，3 小时和 24 小时) 可抑制对乙酰氨基酚 (Acetaminophen (HY-66005)) 诱导的细胞损伤，减少 AML-12 细胞中增加的氧化应激和细胞凋亡[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> LT-630 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | LT-630 (10-40 mg/kg，静脉注射，APAP 给药前) 通过消除 ROS 来抑制对乙酰氨基酚 (APAP) 诱导的小鼠氧化应激和肝细胞凋亡[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C19H17FN4O3 |
| Molar Mass | 368.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang GD, et al. A novel HDAC6 inhibitor attenuate APAP-induced liver injury by regulating MDH1-mediated oxidative stress. Int Immunopharmacol. 2024 Mar 13;131:111861. |